RBC remains buyer of Verve Therapeutics after enrollment pause

RBC Capital keeps an Outperform rating on Verve Therapeutics after the company paused its first-generation PCSK9 study enrollment because one patient experienced Grade 3 transient alanine aminotransferase elevation and thrombocytopenia. The exact etiology remains unknown and the debate on whether this is lipid nanoparticle or the editor is here to stay, but it is likely the former, the analyst tells investors in a research note after speaking with management. RBC says that while the setback today is unfortunate, it remains buyers of the stock. It believes this therapy can be ultimately delivered safely and continues to like an approach that may solve compliance.